Geron Corporation is a Menlo Park, California–based biopharmaceutical company founded in 1990. The company’s early focus was on human embryonic stem cell research, but Geron sold off that line of business in 2013 to concentrate its resources on telomerase inhibition for the treatment of hematologic myeloid malignancies, which are cancers that originate in bone marrow or immune system cells. Telomerase is a naturally occurring enzyme that enables ongoing reproduction of tumor cells in many types of cancer. Using a proprietary nucleic acid chemistry process, Geron designed and developed Imetelstat as a telomerase activity inhibitor aimed at stopping or slowing tumor growth in patients with cancer. As of March 2014, all existing and proposed clinical trials for Imetelstat were placed on full hold by the U.S. ...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles